{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:36:04Z","timestamp":1791005764845,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The risk for atherosclerotic disease is increased 1.5- to 2.0-fold among persons with HIV (PWH). Increased activation of the renin-angiotensin-aldosterone system may contribute to increased arterial inflammation in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the effects of eplerenone on arterial inflammation among well-treated PWH without known cardiovascular disease (CVD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Well-treated PWH who participated in the double-blinded, placebo-controlled, Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV (MIRACLE HIV) study between February 2017 and March 2022 assessing the effects of eplerenone on myocardial perfusion were invited to participate in the Mineralocorticoid Receptor Antagonism By Eplerenone to Lower Arterial Inflammation in HIV (MIRABELLA) substudy if there was no current statin use. Participants were enrolled in the MIRABELLA study and underwent additional <jats:sup>18<\/jats:sup>F-fludeoxyglucose\u2013positron emission tomography\/computed tomography (<jats:sup>18<\/jats:sup>F-FDG PET\/CT) imaging of the aorta and carotid arteries to assess arterial inflammation over 12 months of treatment with eplerenone vs placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Eplerenone, 50 mg, twice a day vs identical placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was change in target to background ratio (TBR), a measure of arterial wall inflammation, in the index vessel after 12 months of treatment. The index vessel was defined as the vessel (aorta, left carotid artery, or right carotid artery) with the highest TBR at baseline in each participant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 26 participants (mean [SD] age, 54 [7] years; 18 male [69%]) were enrolled in the study. Treatment groups (eplerenone, 13 vs placebo, 13) were of similar age, sex, and body mass index. Eplerenone was associated with a reduction in TBR of the primary end point, the index vessel (eplerenone vs placebo: model treatment effect, \u22120.31; 95% CI, \u22120.50 to \u22120.11; <jats:italic>P<\/jats:italic>\u2009=\u2009.006; percentage change, \u221212.4% [IQR, \u221221.9% to \u22122.6%] vs 5.1% [IQR, \u22121.6% to 11.0%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.003). We further observed a significant reduction of the TBR of the most diseased segment (MDS) of the index vessel (eplerenone vs placebo: \u221219.1% [IQR, \u221227.0% to \u221211.9%] vs 6.8% [IQR, \u22129.1% to 12.1%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.007). A similar result was seen assessing the index vessel of the carotids (eplerenone vs placebo: \u221210.0% [IQR, \u221221.8% to 3.6%] vs 9.7% [IQR, \u22129.8% to 15.9%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.046). Reduction in the TBR of MDS of the index vessel on <jats:sup>18<\/jats:sup>F-FDG PET\/CT correlated with improvement in the stress myocardial blood flow on cardiac magnetic resonance imaging (Spearman \u03c1\u2009=\u2009\u22120.67; <jats:italic>P<\/jats:italic>\u2009=\u2009.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion and Relevance<\/jats:title><jats:p>In this small randomized clinical trial, eplerenone was associated with reduction in arterial inflammation among well-treated PWH without known CVD. In addition, reductions in arterial inflammation as measured by <jats:sup>18<\/jats:sup>F-FDG PET\/CT were related to improvements in stress myocardial perfusion. Further larger studies should explore whether eplerenone is a potential treatment strategy for inflammatory-mediated CVD in PWH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02740179\">NCT02740179<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.4578","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T16:00:44Z","timestamp":1702483244000},"page":"189","source":"Crossref","is-referenced-by-count":10,"title":["Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV"],"prefix":"10.1001","volume":"9","author":[{"given":"Suman","family":"Srinivasa","sequence":"first","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady","family":"Abohashem","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allie R.","family":"Walpert","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn N.","family":"Dunderdale","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjna","family":"Iyengar","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Shen","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jerosch-Herold","sequence":"additional","affiliation":[{"name":"Cardiovascular Division of Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"deFilippi","sequence":"additional","affiliation":[{"name":"INOVA Heart and Vascular Institute, Falls Church, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K.","family":"Robbins","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Cardiovascular Division of Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail K.","family":"Adler","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Tawakol","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Grinspoon","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"hbr230023r1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/jamacardio.2016.0846","article-title":"Effects of antiretroviral therapy on immune function and arterial inflammation in treatment-naive patients with HIV infection.","volume":"1","author":"Zanni","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"8","key":"hbr230023r2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.","volume":"210","author":"Hunt","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"hbr230023r3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2012.6698","article-title":"Arterial inflammation in patients with HIV.","volume":"308","author":"Subramanian","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"hbr230023r4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/QAI.0000000000000138","article-title":"Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients.","volume":"66","author":"Tawakol","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"hbr230023r5","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1210\/jc.2015-1461","article-title":"RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients.","volume":"100","author":"Srinivasa","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"hbr230023r6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/cen.v97.5","article-title":"Role of renin-angiotensin-aldosterone system activation and other metabolic variables in relation to arterial inflammation in HIV.","volume":"97","author":"Shen","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"hbr230023r7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/cid\/ciad310","article-title":"Randomized placebo-controlled trial to evaluate effects of eplerenone on myocardial perfusion and function among persons with HIV\u2014results from the MIRACLE HIV study.","volume":"77","author":"Srinivasa","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"hbr230023r8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1161\/CIRCIMAGING.113.000382","article-title":"Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET\/CT study.","volume":"6","author":"Abdelbaky","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"12","key":"hbr230023r9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jcmg.2013.08.006","article-title":"Measurement of arterial activity on routine FDG PET\/CT images improves prediction of risk of future CV events.","volume":"6","author":"Figueroa","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"20","key":"hbr230023r10","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/01.CIR.0000097000.51723.6F","article-title":"Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II\/NG-nitro-L-arginine methyl ester-induced myocardial injury.","volume":"108","author":"Oestreicher","year":"2003","journal-title":"Circulation"},{"issue":"22","key":"hbr230023r11","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.jacc.2018.09.038","article-title":"IL-1\u00df inhibition reduces atherosclerotic inflammation in HIV infection.","volume":"72","author":"Hsue","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hbr230023r12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study.","volume":"62","author":"Tawakol","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hbr230023r13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0735-1097(03)00166-9","article-title":"Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes.","volume":"41","author":"Di Carli","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"hbr230023r14","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.3390\/ijms20225563","article-title":"Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases.","volume":"20","author":"Zanatta","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"15","key":"hbr230023r15","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/eurheartj\/ehp205","article-title":"Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease.","volume":"30","author":"Recio-Mayoral","year":"2009","journal-title":"Eur Heart J"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2813174\/jamacardiology_srinivasa_2023_br_230023_1706752529.24788.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:02:14Z","timestamp":1707926534000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2813174"}},"subtitle":["The MIRABELLA HIV Study"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.4578","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}